What are the recommended guanfacine (Intuniv extended‑release and Tenex immediate‑release) dosing guidelines for treating attention‑deficit/hyperactivity disorder and anxiety in children, adolescents, and adults?

Guanfacine Dosing for ADHD and Anxiety

For ADHD in children and adolescents, start guanfacine extended-release (Intuniv) at 1 mg once daily and titrate by no more than 1 mg per week to a target dose of 0.1 mg/kg/day (typically 1-4 mg/day), with doses up to 0.12 mg/kg potentially providing additional benefit if tolerated 1, 2.

ADHD Treatment: Extended-Release Formulation (Intuniv)

Dosing Algorithm

Starting dose:

• Begin at 1 mg once daily (morning or evening) 1, 2
• Do not take with high-fat meals (increases exposure by ~75% for Cmax and ~40% for AUC) 2

Titration:

• Increase in increments of no more than 1 mg per week 2
• Target dose: 0.1 mg/kg/day as a rule of thumb 1
• Effective range: 0.05-0.08 mg/kg once daily, with doses up to 0.12 mg/kg/day potentially providing additional clinical benefit 1, 3
• Maximum approved dose: 4 mg/day for children/adolescents 2

Age-specific considerations:

• Children (6-12 years): 1-4 mg/day 2
• Adolescents (13-17 years): 1-7 mg/day in clinical trials, though FDA approval remains at 4 mg/day maximum 2, 4
• Children have higher exposure than adolescents at the same dose due to lower body weight 2

Timing of administration:

• Can be given morning or evening with equivalent efficacy 1, 5
• Evening dosing may be preferable due to somnolence/fatigue side effects, though no significant difference in efficacy was found 1

Clinical Context

Treatment positioning:

• Guanfacine is a second-line treatment for ADHD; stimulants remain first-line due to larger effect sizes 1
• In Europe, guanfacine is only approved when stimulants are not suitable, not tolerated, or ineffective 1
• Consider as first-line in specific comorbidities: tic disorders, Tourette's syndrome, substance use disorders, or disruptive behavior disorders 1

Onset of action:

• Treatment effects typically observed after 2-4 weeks, unlike stimulants which work immediately 1

Drug interactions requiring dose adjustment:

• Strong/moderate CYP3A4 inhibitors (ketoconazole, erythromycin, fluconazole): Reduce guanfacine to 50% of target dose 2, 6
• Strong/moderate CYP3A4 inducers (rifampin, efavirenz): Consider titrating up to double the target dose over 1-2 weeks (max 8 mg/day during co-administration) 2, 6

Discontinuation

Taper gradually:

• Decrease by no more than 1 mg every 3-7 days to avoid rebound hypertension 2

Immediate-Release Formulation (Tenex)

Critical distinction: Immediate-release guanfacine (Tenex) has different pharmacokinetics and is not FDA-approved for ADHD 1. The extended-release formulation has 58% relative bioavailability compared to immediate-release, with 60% lower Cmax and 43% lower AUC 2. Do not substitute on a mg-per-mg basis 2.

If switching from immediate-release to extended-release: discontinue immediate-release and titrate extended-release as directed above 2.

Anxiety Treatment

Guanfacine is not FDA-approved for anxiety disorders 7. The evidence provided does not support guanfacine as a primary treatment for anxiety. While some research suggests potential benefits for affective dysregulation in ADHD patients 8, and guanfacine may be considered when ADHD co-occurs with anxiety 1, there are no established dosing guidelines for anxiety as a primary indication.

For anxiety disorders in children and adolescents, SSRIs and SNRIs (particularly duloxetine, which has FDA approval for generalized anxiety disorder in children ≥7 years) are the evidence-based pharmacological treatments 7.

Safety Monitoring

Before initiating and during treatment:

• Measure heart rate and blood pressure prior to initiation, after dose increases, and periodically during therapy 2
• Monitor for hypotension, bradycardia, and syncope—particularly in patients taking antihypertensives or at risk for these conditions 1, 2

Most common adverse effects (≥5%):

• Somnolence (38.6-44.3%), fatigue, headache, lethargy, hypotension, nausea, irritability, insomnia, dizziness, abdominal pain 1, 2, 9
• Most adverse events are mild-to-moderate and emerge within first 2 weeks, generally resolving by study end 10, 11
• Approximately 80% of patients experience at least one treatment-emergent adverse event vs. 66.5% with placebo 9

Warnings:

• Hypotension/bradycardia, somnolence/sedation, cardiac conduction abnormalities 1
• Advise patients to avoid dehydration and overheating 2
• Caution against operating heavy equipment or driving until response is known 2

Special Populations

Hepatic or renal impairment:

• Dose reduction may be required in clinically significant impairment 2
• Guanfacine is primarily metabolized via CYP3A4 and excreted predominantly renally 1

Adults:

• While guanfacine has FDA approval for adults with ADHD, the evidence base is strongest for children and adolescents 9
• More clinical studies are needed in adults 9